Siegfried, Jill M <br/><br/>
Combining the multitargeted tyrosine kinase inhibitor vandetanib with the antiestrogen fulvestrant enhances its antitumor effect in non-small cell lung cancer.  [electronic resource] 

 -  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer  Mar 2012 
 - 485-95 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural 
<br/><br/><label>ISSN: </label>1556-1380 
<br/><br/><label>Standard No.: </label>10.1097/JTO.0b013e31824177ea  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antineoplastic Combined Chemotherapy Protocols<br/>Apoptosis--drug effects<br/>Blotting, Western<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>Cell Proliferation--drug effects<br/>Drug Synergism<br/>Enzyme-Linked Immunosorbent Assay<br/>ErbB Receptors--antagonists & inhibitors<br/>Estradiol--analogs & derivatives<br/>Estrogen Receptor Modulators--pharmacology<br/>Estrogens--pharmacology<br/>Female<br/>Fluorescent Antibody Technique<br/>Fulvestrant<br/>Humans<br/>Immunoenzyme Techniques<br/>Lung Neoplasms--drug therapy<br/>Mice<br/>Mice, SCID<br/>Piperidines--pharmacology<br/>Protein Kinase Inhibitors--pharmacology<br/>Protein-Tyrosine Kinases--antagonists & inhibitors<br/>Quinazolines--pharmacology<br/>RNA, Messenger--genetics<br/>Real-Time Polymerase Chain Reaction<br/>Tumor Cells, Cultured<br/>Vascular Endothelial Growth Factor A--antagonists & inhibitors<br/>Vascular Endothelial Growth Factor Receptor-3--antagonists & inhibitors